Condition: Cancer Treatment-Induced Thrombocytopenia · Sponsor: Qilu Pharmaceutical Co., Ltd.
To evaluate the efficacy and safety of QL0911 in cancer treatment-induced thrombocytopenia. Thrombocytopenia is a low number of platelets in the blood. Sometimes, thrombocytopenia is a side effect of cancer treatment.
This description comes directly from the study's public registry record.
Jun Ma · 0451-84883471 · majun0322@126.com
Shukui Qin · 025-84453932 · qinsk81@163.com
Always discuss trial participation with your own doctor first.
| Harbin First Hospital | Harbin, China | Recruiting |
| Nanjing Tianyinshan Hospital | Nanjing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06456528